ETF Home ETF List Shorted Stocks Home About

ETF Holdings Breakdown of INSM

Stock NameInsmed Inc
TickerINSM(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINUS4576693075
LEI529900Q55QAG41CCAC11

INSM institutional holdings

The adjusted close for INSM on 2026-01-15 was 159.27

The following institutional investment holdings of INSM have been identified

Date ETF ISIN/Name Num Shares Book value Derived Price per Share Comment
2026-01-15 IE00019GPKX6 (iShares MSCI ACWI UCITS ETF SGD Hedged (Acc)) 58,077USD 9,249,924 -2.8% 159.27  
2026-01-15 IE0002EKOXU6 (iShares Russell 1000 Value UCITS ETF) 110 1.8%USD 17,520 -0.8% 159.27  
2026-01-15 IE0009QS7W62 (iShares MSCI World Health Care Sector ESG UCITS ETF USD (Acc)) 13,040USD 2,076,881 -2.6% 159.27  
2026-01-15 IE0009VWHAE6 (iShares US Equity Enhanced Active UCITS ETF USD (Acc)) 5,450USD 868,022 -2.6% 159.27  
2026-01-15 IE000D3BWBR2 (iShares S&P 500 Swap UCITS ETF USD (Dist)) 18,974 200.0%USD 3,021,989 202.6% 159.27  
2026-01-15 IE000D8XC064 (iShares World Equity Enhanced Active UCITS ETF USD (Acc)) 1,199USD 190,965 -2.6% 159.27  
2026-01-15 IE000G2LIHG9 (iShares MSCI USA ESG Screened UCITS ETF EUR Hedged (Acc)) 70,098 0.1%USD 11,164,508 -2.6% 159.27  
2026-01-15 IE000KJPDY61 (iShares World Equity High Income UCITS ETF USD Inc) 5USD 796 -2.6% 159.20 Warning! :Potential incorrect reporting.Incorrect share price reported. Should be 159.27 not 159.20. May be due to incorrect reporting of currency . Could be EUR or USD instead 
2026-01-15 IE000NITTFF2 (iShares Russell 1000 Growth UCITS ETF) 3,453 2.3%USD 549,959 -0.3% 159.27  
2026-01-15 IE000OHHIBC6 (iShares Core MSCI World UCITS ETF USD (Dist)) 333,929 0.1%USD 53,184,872 -2.6% 159.27  
2026-01-15 IE000WHL2ZK1 (iShares U.S. Equity High Income UCITS ETF USD Inc) 89USD 14,175 -2.6% 159.27  
2026-01-15 IE00B0M62Q58 (iShares MSCI World UCITS ETF USD (Dist)) 21,864USD 3,482,279 -2.6% 159.27  
2026-01-15 IE00B14X4M10 (iShares MSCI North America UCITS ETF USD (Dist) USD) 4,330USD 689,639 -2.6% 159.27  
2026-01-15 IE00B42YS929 (iShares MSCI World GBP Hedged UCITS ETF (Acc)) 1,357USD 161,465 -2.1% 118.99 Warning! :Potential incorrect reporting.Incorrect share price reported. Should be 159.27 not 118.99. May be due to incorrect reporting of currency . Could be EUR or USD insteadIE00B42YS929 incorrectly reporting value of holding as USD actually is reported in GBP
2026-01-15 IE00B4L5Y983 (iShares Core MSCI World UCITS ETF USD (Acc)) 333,929 0.1%USD 53,184,872 -2.6% 159.27  
2026-01-15 IE00B52SFT06 (iShares MSCI USA UCITS ETF USD (Acc)) 11,618 1.8%USD 1,850,399 -0.8% 159.27  
2026-01-15 IE00B53SZB19 (iShares NASDAQ 100 UCITS ETF USD (Acc)) 279,548 -0.1%USD 44,523,610 -2.8% 159.27  
2026-01-15 IE00B6R52259 (iShares MSCI ACWI UCITS ETF) 58,077USD 9,249,924 159.27  
2026-01-15 IE00BD1F4K20 (iShares MSCI USA Mid-Cap Equal Weight UCITS ETF USD (Acc)) 5,035USD 801,924 -2.6% 159.27  
2026-01-15 IE00BD1F4N50 (iShares Edge MSCI USA Momentum Factor UCITS ETF USD (Acc) GBP) 6,116 -3.0%USD 974,095 -5.7% 159.27  
2026-01-15 IE00BD45YS76 (iShares Core MSCI World UCITS ETF GBP Hedged (Dist)) 333,929 0.1%USD 53,184,872 -2.6% 159.27  
2026-01-15 IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)) 146,232 0.5%USD 23,290,371 -2.2% 159.27  
2026-01-15 IE00BFF5RZ82 (iShares Edge MSCI USA Momentum Factor UCITS ETF USD (Dist)) 6,116 -3.0%USD 974,095 -5.7% 159.27  
2026-01-15 IE00BFNM3G45 (iShares MSCI USA ESG Screened UCITS ETF USD (Acc)) 70,098 0.1%USD 11,164,508 -2.6% 159.27  
2026-01-15 IE00BFNM3H51 (iShares MSCI USA ESG Screened UCITS ETF USD (Dist)) 70,098 -0.3%USD 11,164,508 -3.1% 159.27  
2026-01-15 IE00BFNM3J75 (iShares MSCI World ESG Screened UCITS ETF) 18,303USD 2,915,119 -2.6% 159.27  
2026-01-15 IE00BFNM3K80 (iShares MSCI World ESG Screened UCITS ETF USD (Dist)) 18,303USD 2,915,119 -2.6% 159.27  
2026-01-15 IE00BG11HV38 (iShares MSCI World ESG Enhanced UCITS ETF USD Inc GBP) 17,488USD 2,785,314 -2.6% 159.27  
2026-01-15 IE00BHZPJ569 (iShares MSCI World ESG Enhanced UCITS ETF USD Acc GBP) 17,488USD 2,785,314 -2.6% 159.27  
2026-01-15 IE00BHZPJ890 (iShares MSCI USA ESG Enhanced UCITS ETF USD (Dist)) 25,223 0.2%USD 4,017,267 -2.5% 159.27  
2026-01-15 IE00BJ5JNZ06 (iShares MSCI World Health Care Sector ESG UCITS ETF) 13,040USD 2,076,881 -2.6% 159.27  
2026-01-15 IE00BKBF6H24 (iShares Core MSCI World UCITS ETF) 333,929 0.1%USD 53,184,872 -2.6% 159.27  
2026-01-15 IE00BMTX1Y45 (iShares S&P 500 Swap UCITS ETF USD (Acc)) 18,974 200.0%USD 3,021,989 202.6% 159.27  
2026-01-15 IE00BMXC7W70 (iShares MSCI World Paris-Aligned Climate UCITS ETF USD (Acc)) 418USD 66,575 -2.6% 159.27  
2026-01-15 IE00BN92ZL31 (iShares MSCI World Paris-Aligned Climate UCITS ETF USD (Dist)) 418USD 66,575 -2.6% 159.27  
2026-01-15 IE00BP3QZ825 (iShares Edge MSCI World Momentum Factor UCITS ETF) 23,903USD 3,807,031 -2.6% 159.27  
2026-01-15 IE00BP3QZD73 (iShares MSCI World Mid-Cap Equal Weight UCITS ETF USD (Acc)) 2,636USD 419,836 -2.6% 159.27  
2026-01-15 IE00BYVQ9F29 (iShares NASDAQ 100 UCITS ETF) 279,548 -0.1%USD 44,523,610 -2.8% 159.27  
2026-01-15 IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc)) 146,232 0.5%USD 23,290,371 -2.2% 159.27  
2026-01-14 IE00B441G979 (iShares MSCI World EUR Hedged UCITS ETF (Acc)) 14,160USD 1,985,072 -0.2% 140.19 Warning! :Potential incorrect reporting.Incorrect share price reported. Should be 159.27 not 140.19. May be due to incorrect reporting of currency . Could be EUR or USD insteadIE00B441G979 incorrectly reporting value of holding as USD actually is reported in EUR
Total =2,782,834 USD 442,897,117
Book value of shares is calculated on the adjusted close price of each day (row).

News associated with INSM

Analysts Set Insmed, Inc. (NASDAQ:INSM) Price Target at $139.86
Insmed, Inc. (NASDAQ:INSM – Get Free Report) has been assigned an average rating of “Moderate Buy” from the seventeen brokerages that are covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a hold recommendation and sixteen have assigned a buy recommendation to the company. The average 1-year target price among brokerages […] - 2025-09-17 02:58:45
Insmed (NASDAQ:INSM) Reaches New 12-Month High on Analyst Upgrade
Shares of Insmed, Inc. (NASDAQ:INSM – Get Free Report) hit a new 52-week high on Monday after Guggenheim raised their price target on the stock from $125.00 to $172.00. Guggenheim currently has a buy rating on the stock. Insmed traded as high as $146.91 and last traded at $145.86, with a volume of 288114 shares […] - 2025-09-10 02:26:50
Notable ETF Outflow Detected - XBI, ALNY, HALO, INSM
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR S&P Biotech ETF (Symbol: XBI) where we have detected an approximate $119.6 million dollar outflow -- that's a 2.2% decrease week over week - 2025-08-28 11:56:11
Insmed (NASDAQ:INSM) Earns Outperform Rating from Analysts at William Blair
Stock analysts at William Blair initiated coverage on shares of Insmed (NASDAQ:INSM – Get Free Report) in a research note issued on Wednesday, MarketBeat Ratings reports. The firm set an “outperform” rating on the biopharmaceutical company’s stock. Other research analysts also recently issued reports about the stock. Truist Financial upped their target price on shares […] - 2025-08-22 02:54:45
The Goldman Sachs Group Forecasts Strong Price Appreciation for Insmed (NASDAQ:INSM) Stock
Insmed (NASDAQ:INSM – Get Free Report) had its target price increased by equities researchers at The Goldman Sachs Group from $114.00 to $142.00 in a research note issued to investors on Wednesday,Benzinga reports. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. The Goldman Sachs Group’s price target indicates a potential upside […] - 2025-08-15 07:10:57
INSM Crosses Above Average Analyst Target
In recent trading, shares of Insmed Inc (Symbol: INSM) have crossed above the average analyst 12-month target price of $119.12, changing hands for $122.00/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuati - 2025-08-13 10:41:52
Insmed (NASDAQ:INSM) Reaches New 1-Year High Following Analyst Upgrade
Insmed, Inc. (NASDAQ:INSM – Get Free Report)’s share price hit a new 52-week high during mid-day trading on Monday after Wells Fargo & Company raised their price target on the stock from $119.00 to $130.00. Wells Fargo & Company currently has an overweight rating on the stock. Insmed traded as high as $113.41 and last […] - 2025-08-13 02:23:00
XBI, ALNY, INSM, INCY: Large Outflows Detected at ETF
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR S&P Biotech ETF (Symbol: XBI) where we have detected an approximate $202.3 million dollar outflow -- that's a 4.3% decrease week over week - 2025-08-12 11:55:54
Insmed, Inc. (NASDAQ:INSM) Shares Purchased by Charles Schwab Investment Management Inc.
Charles Schwab Investment Management Inc. raised its stake in shares of Insmed, Inc. (NASDAQ:INSM – Free Report) by 3.6% during the 1st quarter, Holdings Channel reports. The institutional investor owned 1,602,655 shares of the biopharmaceutical company’s stock after buying an additional 56,048 shares during the period. Charles Schwab Investment Management Inc.’s holdings in Insmed were […] - 2025-08-12 05:59:02
Mackenzie Financial Corp Acquires 2,220 Shares of Insmed, Inc. (NASDAQ:INSM)
Mackenzie Financial Corp lifted its holdings in Insmed, Inc. (NASDAQ:INSM – Free Report) by 20.4% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 13,103 shares of the biopharmaceutical company’s stock after buying an additional 2,220 shares during the quarter. Mackenzie Financial Corp’s holdings in […] - 2025-08-06 05:07:44
Insmed, Inc. (NASDAQ:INSM) Shares Acquired by Cwm LLC
Cwm LLC grew its holdings in Insmed, Inc. (NASDAQ:INSM – Free Report) by 24.5% in the 1st quarter, HoldingsChannel.com reports. The fund owned 2,052 shares of the biopharmaceutical company’s stock after buying an additional 404 shares during the quarter. Cwm LLC’s holdings in Insmed were worth $157,000 as of its most recent SEC filing. Several […] - 2025-07-29 04:28:55
Allianz Asset Management GmbH Has $5.74 Million Holdings in Insmed, Inc. (NASDAQ:INSM)
Allianz Asset Management GmbH raised its stake in shares of Insmed, Inc. (NASDAQ:INSM – Free Report) by 4.9% in the first quarter, Holdings Channel.com reports. The firm owned 75,284 shares of the biopharmaceutical company’s stock after buying an additional 3,534 shares during the period. Allianz Asset Management GmbH’s holdings in Insmed were worth $5,743,000 as […] - 2025-07-28 05:46:50
Insmed, Inc. (NASDAQ:INSM) Shares Bought by Xponance Inc.
Xponance Inc. boosted its stake in shares of Insmed, Inc. (NASDAQ:INSM – Free Report) by 5.3% during the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 13,359 shares of the biopharmaceutical company’s stock after buying an additional 670 shares during the period. Xponance Inc.’s holdings in Insmed […] - 2025-07-17 06:35:03
Envestnet Asset Management Inc. Grows Holdings in Insmed, Inc. (NASDAQ:INSM)
Envestnet Asset Management Inc. raised its position in Insmed, Inc. (NASDAQ:INSM – Free Report) by 26.9% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 325,307 shares of the biopharmaceutical company’s stock after purchasing an additional 68,949 shares during the quarter. Envestnet Asset Management […] - 2025-07-16 07:23:19
Sara Bonstein Sells 57,764 Shares of Insmed, Inc. (NASDAQ:INSM) Stock
Insmed, Inc. (NASDAQ:INSM – Get Free Report) CFO Sara Bonstein sold 57,764 shares of the company’s stock in a transaction on Monday, July 7th. The shares were sold at an average price of $95.86, for a total value of $5,537,257.04. Following the completion of the sale, the chief financial officer owned 84,017 shares in the […] - 2025-07-11 05:13:00
Teacher Retirement System of Texas Sells 2,654 Shares of Insmed, Inc. (NASDAQ:INSM)
Teacher Retirement System of Texas lessened its holdings in shares of Insmed, Inc. (NASDAQ:INSM – Free Report) by 5.5% during the 1st quarter, Holdings Channel.com reports. The firm owned 45,683 shares of the biopharmaceutical company’s stock after selling 2,654 shares during the period. Teacher Retirement System of Texas’ holdings in Insmed were worth $3,485,000 at […] - 2025-07-09 05:48:57
Brokerages Set Insmed, Inc. (NASDAQ:INSM) Target Price at $106.80
Shares of Insmed, Inc. (NASDAQ:INSM – Get Free Report) have earned an average rating of “Buy” from the seventeen brokerages that are presently covering the stock, MarketBeat Ratings reports. Seventeen equities research analysts have rated the stock with a buy recommendation. The average 12-month price target among brokers that have updated their coverage on the […] - 2025-07-04 02:40:47
Insmed, Inc. (NASDAQ:INSM) CFO Sara Bonstein Sells 57,765 Shares
Insmed, Inc. (NASDAQ:INSM – Get Free Report) CFO Sara Bonstein sold 57,765 shares of the stock in a transaction on Monday, June 23rd. The shares were sold at an average price of $101.78, for a total value of $5,879,321.70. Following the completion of the sale, the chief financial officer now owns 93,536 shares in the […] - 2025-06-27 05:06:55
Avior Wealth Management LLC Raises Holdings in Insmed, Inc. (NASDAQ:INSM)
Avior Wealth Management LLC lifted its holdings in shares of Insmed, Inc. (NASDAQ:INSM – Free Report) by 82.2% during the first quarter, according to its most recent disclosure with the SEC. The fund owned 4,151 shares of the biopharmaceutical company’s stock after acquiring an additional 1,873 shares during the period. Avior Wealth Management LLC’s holdings […] - 2025-06-23 05:12:58
Is Insmed Stock Overvalued at $98?
Insmed Inc (NASDAQ: INSM) was nothing short of a juggernaut last month, skyrocketing 45%, while the S&P500 index gained 3% during the same period. What’s fueling the fire? Insmed announced that its Phase IIb trial for treprostinil palmitil inhalation powder (TPIP) in pulmonar - 2025-06-17 03:35:22
Notable ETF Outflow Detected - IWO, SFM, INSM, FTAI
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Russell 2000 Growth ETF (Symbol: IWO) where we have detected an approximate $123.7 million dollar outflow -- that's a 1.1% decrease week ove - 2025-06-16 11:49:52
Insmed Incorporated (NASDAQ:INSM) CFO Sells $5,148,105.92 in Stock
Insmed Incorporated (NASDAQ:INSM – Get Free Report) CFO Sara Bonstein sold 57,766 shares of the company’s stock in a transaction on Tuesday, June 10th. The stock was sold at an average price of $89.12, for a total transaction of $5,148,105.92. Following the sale, the chief financial officer now directly owns 103,412 shares in the company, […] - 2025-06-16 05:18:57
Park Avenue Securities LLC Has $842,000 Holdings in Insmed Incorporated (NASDAQ:INSM)
Park Avenue Securities LLC boosted its position in shares of Insmed Incorporated (NASDAQ:INSM – Free Report) by 38.7% during the 1st quarter, Holdings Channel reports. The institutional investor owned 11,036 shares of the biopharmaceutical company’s stock after purchasing an additional 3,081 shares during the quarter. Park Avenue Securities LLC’s holdings in Insmed were worth $842,000 […] - 2025-06-13 05:18:50
Morgan Stanley Increases Insmed (NASDAQ:INSM) Price Target to $102.00
Insmed (NASDAQ:INSM – Get Free Report) had its price objective lifted by stock analysts at Morgan Stanley from $90.00 to $102.00 in a report released on Wednesday,Benzinga reports. The firm currently has an “overweight” rating on the biopharmaceutical company’s stock. Morgan Stanley’s target price suggests a potential upside of 5.28% from the stock’s previous close. […] - 2025-06-13 04:40:52
Insmed (NASDAQ:INSM) Stock Price Expected to Rise, Royal Bank of Canada Analyst Says
Insmed (NASDAQ:INSM – Get Free Report) had its target price raised by research analysts at Royal Bank of Canada from $99.00 to $106.00 in a report issued on Wednesday,Benzinga reports. The brokerage presently has an “outperform” rating on the biopharmaceutical company’s stock. Royal Bank of Canada’s price target would suggest a potential upside of 9.41% […] - 2025-06-13 04:40:51
Insmed (NASDAQ:INSM) Stock Price Expected to Rise, Mizuho Analyst Says
Insmed (NASDAQ:INSM – Get Free Report) had its price objective lifted by equities research analysts at Mizuho from $96.00 to $110.00 in a report issued on Wednesday,Benzinga reports. The firm presently has an “outperform” rating on the biopharmaceutical company’s stock. Mizuho’s price target points to a potential upside of 13.54% from the company’s current price. […] - 2025-06-13 04:40:49
Insmed (NASDAQ:INSM) Shares Up 4.5% Following Analyst Upgrade
Insmed Incorporated (NASDAQ:INSM – Get Free Report)’s stock price traded up 4.5% during trading on Wednesday after The Goldman Sachs Group raised their price target on the stock from $100.00 to $112.00. The Goldman Sachs Group currently has a buy rating on the stock. Insmed traded as high as $93.82 and last traded at $95.02. […] - 2025-06-13 02:17:01
INSM Crosses Above Average Analyst Target
In recent trading, shares of Insmed Inc (Symbol: INSM) have crossed above the average analyst 12-month target price of $97.70, changing hands for $97.98/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation - 2025-06-12 08:33:46
Bank of America Increases Insmed (NASDAQ:INSM) Price Target to $109.00
Insmed (NASDAQ:INSM – Free Report) had its price objective boosted by Bank of America from $94.00 to $109.00 in a research report sent to investors on Wednesday,Benzinga reports. They currently have a buy rating on the biopharmaceutical company’s stock. Several other equities analysts have also recently commented on INSM. Stifel Nicolaus reduced their target price […] - 2025-06-12 05:08:53
Wells Fargo & Company Issues Positive Forecast for Insmed (NASDAQ:INSM) Stock Price
Insmed (NASDAQ:INSM – Free Report) had its target price upped by Wells Fargo & Company from $107.00 to $119.00 in a research report sent to investors on Wednesday,Benzinga reports. They currently have an overweight rating on the biopharmaceutical company’s stock. A number of other research firms also recently weighed in on INSM. Stifel Nicolaus decreased […] - 2025-06-12 04:32:54

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.

Copyright Market Footprint Ltd. Privacy Policy